284 related articles for article (PubMed ID: 1657264)
21. Inhibition by glaucocalyxin A of aggregation of rabbit platelets induced by ADP, arachidonic acid and platelet-activating factor, and inhibition of [3H]-PAF binding.
Bin Z; Kun L
Thromb Haemost; 1992 Apr; 67(4):458-60. PubMed ID: 1631795
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of [3H]platelet activating factor (PAF) binding by Zn2+: a possible explanation for its specific PAF antiaggregating effects in human platelets.
Nunez D; Kumar R; Hanahan DJ
Arch Biochem Biophys; 1989 Aug; 272(2):466-75. PubMed ID: 2502069
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological activity of amide derivatives of ginkgolide A.
Hu LH; Chen ZL; Xie YY
J Asian Nat Prod Res; 2001; 3(3):219-27. PubMed ID: 11491398
[TBL] [Abstract][Full Text] [Related]
24. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
25. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
26. Competitive inhibition of tritium-labeled platelet-activating factor binding to rabbit platelet membranes by amiloride and amiloride analogs.
Hwang SB
Biochem Biophys Res Commun; 1989 Aug; 163(1):165-71. PubMed ID: 2549986
[TBL] [Abstract][Full Text] [Related]
27. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.
Földes-Filep E; Braquet P; Filep J
Biochem Biophys Res Commun; 1987 Nov; 148(3):1412-7. PubMed ID: 2825685
[TBL] [Abstract][Full Text] [Related]
28. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
29. An antagonistic activity of etizolam on platelet-activating factor (PAF). In vitro effects on platelet aggregation and PAF receptor binding.
Mikashima H; Takehara S; Muramoto Y; Khomaru T; Terasawa M; Tahara T; Maruyama Y
Jpn J Pharmacol; 1987 Aug; 44(4):387-91. PubMed ID: 2890779
[TBL] [Abstract][Full Text] [Related]
30. Species-dependent differences of high affinity [3H]PAF-binding to platelets from humans and pigs and its inhibition by selected antagonists.
Ostermann G; Lorenz A; Hofmann B; Kertscher HP
J Lipid Mediat; 1991 Nov; 4(3):289-98. PubMed ID: 1662546
[TBL] [Abstract][Full Text] [Related]
31. Ginkgolides and platelet-activating factor binding sites.
Hosford DJ; Domingo MT; Chabrier PE; Braquet P
Methods Enzymol; 1990; 187():433-46. PubMed ID: 2172741
[No Abstract] [Full Text] [Related]
32. Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.
Schattner M; Parini A; Fouque F; Vargaftig BB; Touqui L
Br J Pharmacol; 1989 Apr; 96(4):759-66. PubMed ID: 2787179
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021.
Kurihara K; Wardlaw AJ; Moqbel R; Kay AB
J Allergy Clin Immunol; 1989 Jan; 83(1):83-90. PubMed ID: 2536413
[TBL] [Abstract][Full Text] [Related]
34. Pharmacologic characterization of the rabbit neutrophil receptor for platelet-activating factor.
Paulson SK; Wolf JL; Novotney-Barry A; Cox CP
Proc Soc Exp Biol Med; 1990 Nov; 195(2):247-54. PubMed ID: 2172997
[TBL] [Abstract][Full Text] [Related]
35. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
36. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
37. Antiplatelet aggregation activity of diterpene alkaloids from Spiraea japonica.
Li L; Shen YM; Yang XS; Zuo GY; Shen ZQ; Chen ZH; Hao XJ
Eur J Pharmacol; 2002 Aug; 449(1-2):23-8. PubMed ID: 12163102
[TBL] [Abstract][Full Text] [Related]
38. Presence of specific platelet-activating factor binding sites in the rat retina.
Thierry A; Doly M; Braquet P; Cluzel J; Meyniel G
Eur J Pharmacol; 1989 Apr; 163(1):97-101. PubMed ID: 2545464
[TBL] [Abstract][Full Text] [Related]
39. Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet.
Terashita Z; Imura Y; Nishikawa K
Biochem Pharmacol; 1985 May; 34(9):1491-5. PubMed ID: 2986648
[TBL] [Abstract][Full Text] [Related]
40. Platelet-activating factor and antagonists modulate DNA synthesis in human bone marrow stromal cell cultures.
Rougier F; Dupuis F; Cornu E; Dulery C; Praloran V; Denizot Y
J Lipid Mediat Cell Signal; 1997 Jul; 16(3):147-53. PubMed ID: 9246604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]